Cantabio Pharmaceuticals, Inc. is a preclinical stage biotechnology company, which engages in the commercialization of novel therapies and the intellectual property generated from the research and development activities for Parkinson's, Alzheimer's diseases, and any other related diseases. It focuses on identification and development of small molecule pharmacological chaperones targeting proteins that misfold and aggregated in vivo vivo levels of proteins which display loss of function during disease conditions. The company was founded by Gergely Toth on February 6, 2012 and is headquartered in Palo Alto, CA.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company